Comparative Pharmacology
Head-to-head clinical analysis: MYCOSTATIN versus NUFYMCO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCOSTATIN versus NUFYMCO.
MYCOSTATIN vs NUFYMCO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mycostatin (nystatin) is a polyene antifungal antibiotic that binds to ergosterol in the fungal cell membrane, forming pores that increase membrane permeability, leading to leakage of intracellular contents and cell death.
NUFYMCO is a lipid-regulating agent. Its mechanism involves activation of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma, and reduced VLDL production.
Nystatin suspension: 400,000-600,000 units (4-6 mL) orally four times daily for 7-14 days. Nystatin pastilles: 200,000-400,000 units (1-2 pastilles) orally four to five times daily for 7-14 days.
NUFYMCO is a proprietary combination product; standard adult dosing is one capsule (25 mg bempedoic acid/20 mg ezetimibe) orally once daily.
None Documented
None Documented
Not applicable (nystatin is not absorbed systemically; no meaningful plasma half-life exists). For reference, if absorbed, the terminal half-life would be approximately 4-6 hours, but this is not clinically relevant.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged to 24-36 hours in moderate renal impairment
Nystatin is not absorbed from the gastrointestinal tract, skin, or mucous membranes. After oral administration, virtually all of the drug is excreted unchanged in feces. Renal excretion is negligible (<0.1%).
Renal (60-70% as unchanged drug), biliary/fecal (20-30% as metabolites and unchanged drug)
Category C
Category C
Antifungal
Antifungal